Citation： 程若川. 分化型甲状腺癌术后RAI治疗的分歧与共识. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(7): 779-783. doi: 10.7507/1007-9424.20150204 Copy
| 1. | Regalbuto C, Frasca F, Pellegriti G, et al. Update on thyroid cancer treatment. Future Oncol, 2012, 8(10):1331-1348. |
| 2. | American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214. |
| 3. | Reiners C, Hänscheid H, Luster M, et al. Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol, 2011, 7(10):589-595. |
| 4. | Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid, 2009, 19(12):1381-1391. |
| 5. | Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214. |
| 6. | Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 1994, 97(5):418-428. |
| 7. | Cirocchi R, Trastulli S, Sanguinetti A, et al. Recurrent differentiated thyroid cancer:to cut or to burn. World J Surg Oncol, 2011, 9:89. |
| 8. | Carballo M, Quiros RM. To treat or not to treat:the role of adjuvant radioiodine therapy in thyroid cancer patients. J Oncol, 2012, 2012:1-11. |
| 9. | Livingston EH, McNutt RA. The hazards of evidence-based medicine:assessing variations in care. JAMA, 2011, 306(7):762-763. |
| 10. | Haymart MR, Muenz DG, Stewart AK, et al. Disease severity and radioactive iodine use for thyroid cancer. J Clin Endocrinol Metab, 2013, 98(2):678-686. |
| 11. | Famakinwa OM, Roman SA, Wang TS, et al. ATA practice guidelines for the treatment ofdifferentiated thyroid cancer:were the followed in the United States. Am J Surg, 2010, 199(2):189-198. |
| 12. | Boelaert K. Thyroid gland:revised guidelines for the management of thyroid cancer. Nat Rev Endocrinol, 2010, 6(4):185-186. |
| 13. | Gharib H,Papini E,Paschke R,et al. American Association of Clinical Endocrinologists,Associazione Medici Endoerinologi,and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules,Endocr Pract, 2010,16 Suppl 1:1-43. |
| 14. | Camargo R, Corigliano S, Friguglietti C, et al. Latin American Thyroid Society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol, 2009, 53(9):1167-1175. |
| 15. | Pitoia F, Bueno F, Urciuoli C, et al. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid, 2013, 23(11):1401-1407. |
| 16. | Rondeau G, Tuttle RM. Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States. Semin Nucl Med, 2011, 41(2):89-95. |
| 17. | Durante C, Costante G, Filetti S. Differentiated thyroid carcinoma:defining new paradigms for postoperative management. Endocr Relat Cancer, 2013, 20(4):R141-R154. |
| 18. | Mallick UK. The revised American Thyroid Association management guidelines 2009 for patients with differentiated thyroid cancer:an evidence-based risk-adapted approach. Clin Oncol (R Coll Radiol), 2010, 22(6):472-474. |
| 19. | National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Version 2. 2013. http://guide.medlive.cn/guideline/4800. |
| 20. | Ito Y, Tomoda C, Uruno T, et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg, 2005, 29(7):917-920. |
| 21. | Ito Y, Miyauchi A. Lateral lymph node dissection guided by preoperative and intraoperative findings in differentiated thyroid carcinoma. World J Surg, 2008, 32(5):729-739. |
| 22. | Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis:usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg, 2004, 28(5):498-501. |
| 23. | Ito Y, Fukushima M, Tomoda C, et al. Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastasis to the lateral compartment. Endocr J, 2009, 56(6):759-766. |
| 24. | de Meer SG, Dauwan M, de Keizer B, et al. Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer. World J Surg, 2012, 36(6):1262-1267. |
| 25. | Ibrahimpasic T, Nixon IJ, Palmer F L, et al. Undetectable thyroglobulin after total thyroidectomy in patients with low and intermediate-risk papillary thyroid cancer-is there a need for radioactive iodine therapy? Surgery, 2012, 152(6):1096-1105. |
| 26. | US Cancer Statistics Working Group. United States cancer statistics:1999-2010 incidence and mortality web-based report. Atlanta (GA):Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2014. http://198.246.124.29/cancer/upcr/pdf/USCS-FactSheet.pdf. |
| 27. | Amirian ES, Armstrong TS, Aldape KD, et al. Predictors of survival among pediatric and adult ependymoma cases:a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology, 2012, 39(2):116-124. |
| 28. | Kloos RT. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid, 2009, 19(9):925-928. |
| 29. | Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 2011, 117(19):4439-4446. |
| 30. | Sacks W, Fung CH, Chang JT, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer:a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid, 2010, 20(11):1235-1245. |
| 31. | Şengöz T, Sürücü E, Demir Y, et al. The effects of the factors related to the patient and the disease on the performance of ablation therapy in patients with differentiated thyroid cancer who have received I-131 ablation therapy. Mol Imaging Radionucl Ther, 2012, 21(3):103-109. |
| 32. | Papaleontiou M, Banerjee M, Yang D, et al. Factors that influence radioactive iodine use for thyroid cancer. Thyroid, 2013, 23(2):219-224. |
| 33. | Haymart MR, Banerjee M, Yang D, et al. The relationship between extent of thyroid cancer surgery and use of radioactive iodine. Ann Surg, 2013, 258(2):354-358. |
| 34. | Alexander EK, Larsen PR. Radioiodine for thyroid cancer-is less more? N Engl J Med, 2012, 366(18):1732-1733. |
| 35. | Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma:insights gained from the Mayo Clinic's experience of treating 2 512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc, 2002, 113:241-260. |
| 36. | Nixon IJ, Ganly I, Patel SG, et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid, 2013, 23(6):683-694. |
| 37. | Pacini F, Ito Y, Luster M, et al. Radioactive iodine-refractory differentiated thyroid cancer:unmet needs and future directions. Expert Rev Endocrinol Metab, 2012, 7(5):541-554. |
| 38. | Elfenbein DM, Scheri RP, Roman S, et al. Detection and management of cervical lymph nodes in papillary thyroid cancer. Expert Rev Endocrinol Metab, 2013, 8(4):365-378. |
| 39. | Tuttle RM, Sabra MM. Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer:a practical approach to clinical decision making. Oral Oncol, 2013, 49(7):676-683. |
- 1. Regalbuto C, Frasca F, Pellegriti G, et al. Update on thyroid cancer treatment. Future Oncol, 2012, 8(10):1331-1348.
- 2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214.
- 3. Reiners C, Hänscheid H, Luster M, et al. Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol, 2011, 7(10):589-595.
- 4. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid, 2009, 19(12):1381-1391.
- 5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214.
- 6. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 1994, 97(5):418-428.
- 7. Cirocchi R, Trastulli S, Sanguinetti A, et al. Recurrent differentiated thyroid cancer:to cut or to burn. World J Surg Oncol, 2011, 9:89.
- 8. Carballo M, Quiros RM. To treat or not to treat:the role of adjuvant radioiodine therapy in thyroid cancer patients. J Oncol, 2012, 2012:1-11.
- 9. Livingston EH, McNutt RA. The hazards of evidence-based medicine:assessing variations in care. JAMA, 2011, 306(7):762-763.
- 10. Haymart MR, Muenz DG, Stewart AK, et al. Disease severity and radioactive iodine use for thyroid cancer. J Clin Endocrinol Metab, 2013, 98(2):678-686.
- 11. Famakinwa OM, Roman SA, Wang TS, et al. ATA practice guidelines for the treatment ofdifferentiated thyroid cancer:were the followed in the United States. Am J Surg, 2010, 199(2):189-198.
- 12. Boelaert K. Thyroid gland:revised guidelines for the management of thyroid cancer. Nat Rev Endocrinol, 2010, 6(4):185-186.
- 13. Gharib H,Papini E,Paschke R,et al. American Association of Clinical Endocrinologists,Associazione Medici Endoerinologi,and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules,Endocr Pract, 2010,16 Suppl 1:1-43.
- 14. Camargo R, Corigliano S, Friguglietti C, et al. Latin American Thyroid Society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol, 2009, 53(9):1167-1175.
- 15. Pitoia F, Bueno F, Urciuoli C, et al. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid, 2013, 23(11):1401-1407.
- 16. Rondeau G, Tuttle RM. Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States. Semin Nucl Med, 2011, 41(2):89-95.
- 17. Durante C, Costante G, Filetti S. Differentiated thyroid carcinoma:defining new paradigms for postoperative management. Endocr Relat Cancer, 2013, 20(4):R141-R154.
- 18. Mallick UK. The revised American Thyroid Association management guidelines 2009 for patients with differentiated thyroid cancer:an evidence-based risk-adapted approach. Clin Oncol (R Coll Radiol), 2010, 22(6):472-474.
- 19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Version 2. 2013. http://guide.medlive.cn/guideline/4800.
- 20. Ito Y, Tomoda C, Uruno T, et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg, 2005, 29(7):917-920.
- 21. Ito Y, Miyauchi A. Lateral lymph node dissection guided by preoperative and intraoperative findings in differentiated thyroid carcinoma. World J Surg, 2008, 32(5):729-739.
- 22. Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis:usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg, 2004, 28(5):498-501.
- 23. Ito Y, Fukushima M, Tomoda C, et al. Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastasis to the lateral compartment. Endocr J, 2009, 56(6):759-766.
- 24. de Meer SG, Dauwan M, de Keizer B, et al. Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer. World J Surg, 2012, 36(6):1262-1267.
- 25. Ibrahimpasic T, Nixon IJ, Palmer F L, et al. Undetectable thyroglobulin after total thyroidectomy in patients with low and intermediate-risk papillary thyroid cancer-is there a need for radioactive iodine therapy? Surgery, 2012, 152(6):1096-1105.
- 26. US Cancer Statistics Working Group. United States cancer statistics:1999-2010 incidence and mortality web-based report. Atlanta (GA):Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2014. http://198.246.124.29/cancer/upcr/pdf/USCS-FactSheet.pdf.
- 27. Amirian ES, Armstrong TS, Aldape KD, et al. Predictors of survival among pediatric and adult ependymoma cases:a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology, 2012, 39(2):116-124.
- 28. Kloos RT. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid, 2009, 19(9):925-928.
- 29. Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 2011, 117(19):4439-4446.
- 30. Sacks W, Fung CH, Chang JT, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer:a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid, 2010, 20(11):1235-1245.
- 31. Şengöz T, Sürücü E, Demir Y, et al. The effects of the factors related to the patient and the disease on the performance of ablation therapy in patients with differentiated thyroid cancer who have received I-131 ablation therapy. Mol Imaging Radionucl Ther, 2012, 21(3):103-109.
- 32. Papaleontiou M, Banerjee M, Yang D, et al. Factors that influence radioactive iodine use for thyroid cancer. Thyroid, 2013, 23(2):219-224.
- 33. Haymart MR, Banerjee M, Yang D, et al. The relationship between extent of thyroid cancer surgery and use of radioactive iodine. Ann Surg, 2013, 258(2):354-358.
- 34. Alexander EK, Larsen PR. Radioiodine for thyroid cancer-is less more? N Engl J Med, 2012, 366(18):1732-1733.
- 35. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma:insights gained from the Mayo Clinic's experience of treating 2 512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc, 2002, 113:241-260.
- 36. Nixon IJ, Ganly I, Patel SG, et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid, 2013, 23(6):683-694.
- 37. Pacini F, Ito Y, Luster M, et al. Radioactive iodine-refractory differentiated thyroid cancer:unmet needs and future directions. Expert Rev Endocrinol Metab, 2012, 7(5):541-554.
- 38. Elfenbein DM, Scheri RP, Roman S, et al. Detection and management of cervical lymph nodes in papillary thyroid cancer. Expert Rev Endocrinol Metab, 2013, 8(4):365-378.
- 39. Tuttle RM, Sabra MM. Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer:a practical approach to clinical decision making. Oral Oncol, 2013, 49(7):676-683.
-
Previous Article
甲状腺结节消融治疗的现状及展望 -
Next Article
The Function of Recurrent Laryngeal Nerve and Movement of Vocal Cords in Thyroid Surgery